Patents Examined by Amy E Juedes
  • Immunotoxins, formulations thereof and their use in medicine
    Patent number: 11447548
    Abstract: The present invention provides a composition comprising a first antibody molecule that specifically recognizes CD3 and a second antibody molecule that specifically recognizes CD7, for use in a method of treatment, or preventative treatment of viral infection or viral reactivation in a mammalian subject undergoing immunomodulatory treatment, wherein the first and second antibody molecules are each provided with a toxic moiety. Also provided is a method of treating a mammalian subject having, or being at risk of developing, chronic Graft versus Host disease (cGVHD). Also provided is a related pharmaceutical composition.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: September 20, 2022
    Assignee: Xenikos B.V.
    Inventors: Henricus Gerardus Van Hooren, Maarten Jaap Frijlink, Ypke Vincentius Johannes Maria Van Oosterhout
  • In-vitro methods for the detection of autoimmune diseases or conditions
    Patent number: 11447825
    Abstract: A method for the detection of impaired responsiveness of CD4+ T-cells to regulatory T-cells (Treg), Treg resistance, by measuring the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha, PPARGC1A (PGC-1?) in activated CD4+ T-cells, in particular in patients suffering from relapsing remitting multiple sclerosis. The invention relates to an in vitro screening method for the detection of an autoimmune disease or a condition, comprising the steps of generating a functional gene expression profile by measuring the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha, PPARGC1A (PGC-1?) in Treg-resistant CD4+ T-cells from patients suffering of an autoimmune disease or condition, and comparing the obtained gene expression profile with the expression profile from Treg-sensitive CD4+ T-cells from healthy controls.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: September 20, 2022
    Assignee: Universitätsmedizin der Johannes Gutenberg-Universität Mainz
    Inventors: Bettina Trinschek, Kazuki Satoh, Helmut Jonuleit
  • Regulatory T cell epitopes
    Patent number: 11441122
    Abstract: The present is directed to compositions comprising regulatory T cell epitopes, wherein said epitopes comprise a polypeptide comprising at least a portion of SEQ NOS: 1-14, fragments and/or variants thereof, as well as methods of producing and using the same.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: September 13, 2022
    Assignees: EpiVax Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services Food and Drug Administration
    Inventors: William Martin, Amy S. Rosenberg
  • Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer
    Patent number: 11421034
    Abstract: The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: August 23, 2022
    Assignees: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Katherine E. Lewis, Serena Kimi Perna, Michael Carleton, Ke Xu, Penny Phillips, Dimple Pandya, Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Janine Powers, Ernestine Lee
  • Immunotherapy method comprising administering a combination of immune effector cells and non-target hematopoietic cells
    Patent number: 11419935
    Abstract: The invention provides a system that comprises pharmaceutical agents for use in immunotherapy for reducing the side-effects of an antigen-recognizing receptor against antigen-expressing non-target cells in an individual. The system includes an antigen-recognizing receptor that specifically recognizes an antigen on target cells and at least on one hematopoietic cell type in the individual. The antigen-recognizing receptor is exemplified by chimeric antigen receptors (CAR) be expressed on the surface of an immune effector cells. The system also includes hematopoietic cells resistant to recognition of the same antigen by the antigen-recognizing receptor.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: August 23, 2022
    Assignee: MILTENYI BIOTEC B.V. & CO. KG
    Inventors: Michael Lutteropp, Anne Richter, Andrew Kaiser, Mario Assenmacher, Stefan Miltenyi
  • Antibodies that bind to OX40 and their uses
    Patent number: 11407839
    Abstract: The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: August 9, 2022
    Assignee: Ichnos Sciences SA
    Inventors: Antoine Attinger, Stanislas Blein, Jonathan Albert Back, Rami Lissilaa, Samuel Hou
  • Compositions and methods for inhibiting T cell exhaustion
    Patent number: 11400117
    Abstract: The present invention relates to T cell compositions and methods of using the same in the context of therapy and treatment. In particular, the invention provides T cells that are modified (e.g., genetically and/or functionally) to maintain functionality under conditions in which unmodified T cells display exhaustion. Compositions and methods disclosed herein find use in preventing exhaustion of engineered (e.g., chimeric antigen receptor (CAR) T cells) as well as non-engineered T cells thereby enhancing T cell function (e.g., activity against cancer or infectious disease).
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: August 2, 2022
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Crystal Mackall, Rachel Lynn, Evan Weber, Elena Sotillo
  • BCMA-binding antibodies and uses thereof
    Patent number: 11401336
    Abstract: Antibody species that bind B-Cell Maturation Antigen (BCMA) are provided as well as methods of depleting BCMA-expressing cells in a patient in need thereof, comprising administering a therapeutically effective amount of the antibody species or an entity comprising a BCMA binding fragment thereof. Methods of treating B cell-related disorders associated with BCMA expression in a patient in need thereof are provided, comprising administering to the patient a therapeutically effective amount of the antibody species or an entity comprising a BCMA binding fragment thereof.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: August 2, 2022
    Assignee: CELGENE CORPORATION
    Inventors: Mahan Abbasian, Henry Chan, Kandasamy Hariharan, Jeonghoon Sun, Andrew Wurmser
  • Genetically modified cells and uses thereof
    Patent number: 11400145
    Abstract: The present invention relates generally to a population of stem cells (e.g., iPSCs or HSCs) that comprise nucleic acids encoding a T cell receptor and a chimeric antigen receptor directed to multiple distinct antigenic determinants, for example two distinct tumour antigenic determinants. The present invention is also directed to a population of T cells that co-express a T cell receptor and a chimeric antigen receptor directed to multiple distinct antigenic determinants, such as two distinct tumour antigenic determinants. The cells of the present invention can be derived from chosen donors whose HLA type is compatible with significant sectors of the populations, and are useful in a wide variety of applications, in particular in the context of the therapeutic treatment of neoplastic conditions.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: August 2, 2022
    Assignee: CARTHERICS PTY. LTD.
    Inventors: Richard Boyd, Alan Trounson, Hiroshi Kawamoto, Peter John Hudson, Runzhe Shu
  • BTLA agonist antibodies and uses thereof
    Patent number: 11396545
    Abstract: Antibodies which bind BTLA, and methods of using same, are provided, said antibodies are useful as agents for treating conditions associated with autoimmune disease including treating lupus.
    Type: Grant
    Filed: February 17, 2020
    Date of Patent: July 26, 2022
    Assignee: Eli Lilly and Company
    Inventors: Shane Krummen Atwell, Andrew Charles Vendel, Victor H. Obungu
  • Chimeric antigen receptors targeting CD70
    Patent number: 11396551
    Abstract: The disclosure provides CARs (CARs) that specifically bind to CD70. The disclosure further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The disclosure further relates to therapeutic methods for use of these CARs and engineered immune cells comprising these CARs for the treatment of a condition associated with malignant cells expressing CD70 (e.g., cancer).
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: July 26, 2022
    Assignee: Pfizer Inc.
    Inventors: Surabhi Srivatsa Srinivasan, Niranjana Aditi Nagarajan, Siler Panowski, Yoon Park, Tao Sai, Barbra Johnson Sasu, Thomas John Van Blarcom, Mathilde Brunnhilde Dusseaux, Roman Ariel Galetto
  • Compositions and methods for the treatment of immune related diseases
    Patent number: 11390678
    Abstract: The present invention relates to compositions and methods of using those compositions for the diagnosis and treatment of immune related diseases.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: July 19, 2022
    Assignee: Genentech, Inc.
    Inventors: Hilary Clark, Dan Eaton, Lino Gonzalez, Jr., Jane Grogan, Jason A. Hackney, Kristin Bowles, Xin Yu
  • Materials and methods for modifying the activity of T cells
    Patent number: 11390848
    Abstract: This disclosure provides miRNA/mRNA pairs that can be used to increase the efficacy of T cells or to down-modulate T cell efficacy and restore equilibrium.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: July 19, 2022
    Assignees: Regents of the University of Minnesota, Regents of the University of Michigan, The Ohio State University
    Inventors: Bruce R. Blazar, Keli Hippen, Pavan Reddy, Yaping Sun, Ramiro Garzon
  • MoT cells as a therapeutic screening tool for regulatory t-cell activity
    Patent number: 11391726
    Abstract: The present invention includes a method for screening one or more agents that modulate Regulatory T cell (Treg) activity, the method comprising the steps of: incubating a population CD4+ cells isolated from human blood peripheral mononuclear cells the CD4+ cells in contact with MoT cells in the presence of the one or more agents suspected of modulating Treg activity; detecting activation of the CD4+ cells without or with the agent; and comparing the activation of the CD4+ cells without or with the agent, wherein a change in activation following incubation with the agent relative to the activation of the PBMCs following incubation without the agent indicates that the agent is a modulator of Treg activity.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: July 19, 2022
    Assignees: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY, MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Douglas Lake, Thai H. Ho, Glen J. Weiss
  • Methods for predicting the survival time of patients suffering from a lung cancer
    Patent number: 11385231
    Abstract: The present invention relates to methods for predicting the survival time of patients suffering from a lung cancer.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: July 12, 2022
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE SCIENTIFIQUE), UNIVERSITE DE PARIS, SORBONNE UNIVERSITE, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)
    Inventors: Marie-Caroline Dieu-Nosjean, Wolf Herdman Fridman, Catherine Sautes-Fridman, Priyanka Devi
  • Compositions and methods for in vitro cultivation and/or expansion of regulatory T cells
    Patent number: 11384336
    Abstract: FOXP3+ regulatory T cells (Tregs) can represent powerful adoptive immunotherapies for autoimmune diseases, metabolic diseases, and other chronic inflammatory diseases. The present invention is related to the ability to maintain and expand stable Treg lines and can provide insight into FOXP3+ Treg physiology and can enable feasible strategies of Treg-based immunotherapy.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: July 12, 2022
    Assignee: East Carolina University
    Inventors: Daniel Stephen Wilkinson, Mark D. Mannie
  • ILT3 ligand
    Patent number: 11370839
    Abstract: The present invention provides antibodies and antigen-binding fragments thereof that bind ILT3, ILT3 ligand (i.e., PI16) or a complex between ILT3 and the ILT3 ligand. Methods for determining whether ILT3 and the ILT3 ligand bind together or whether a substance agonizes or antagonizes such binding are also provided.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: June 28, 2022
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Daniel Cua, Holly Cherwinski, Adele Wang, Yi Chen, Barbara Joyce-Shaikh
  • Ex vivo generation of MHCII restricted CD4FOXP3regulatory T cells and therapeutic uses thereof
    Patent number: 11365392
    Abstract: The present invention relates to a method for ex vivo generating and expanding MHCII restricted CD4+ Foxp3+ regulatory T cells, and therapeutic uses thereof. The inventors here demonstrated the optimal conditions for inducing Foxp3 expression in naive CD3+ CD4+ TCR??+ MHCII restricted T following polyclonal or following antigen-specific activation. They also developed an experimental procedure to generate autologous CD8+ T cell lines functionally committed to lyse tumor-antigen specific FOXP3 expressing TCR??+ MHCII restricted T cells, pathogenic CD4+ T cells that favour tumor cell immune evasion. In particular, the present invention relates to a method for generating ex vivo MHCII restricted CD4+ Foxp3+ regulatory T cells having the following phenotype: CD3+ CD4+ Foxp3+.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: June 21, 2022
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), MEDECINE ET INNOVATION, UNIVERSITÉ PARIS DIDEROT—PARIS 7, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Daniel Zagury, Helene Le Buanec, Sophie Duchez, Valerie Schiavon, Armand Bensussan
  • Ex vivo antigen-presenting cells or activated CD-positive T cells for treatment of cancer
    Patent number: 11364264
    Abstract: This disclosure is directed to methods of preparing dendritic cells or other CD40 bearing antigen-presenting cells and methods of treating cancer by using the dendritic cells or other antigen-presenting cells in combination with anti-chemorepellant agents. This disclosure is further directed to methods of preparing T cells and methods of treating cancer, by activated T cells optionally in combination with anti-chemorepellant agents. The antigen presenting cells of the disclosure are activated by incubation with cancer cells and fusion proteins. The T cells of the disclosures are activated by incubation with activated antigen-presenting cells that were activated by incubation with cancer cells and a fusion protein. In particular, the fusion protein comprises an antigen-binding domain, e.g., an antibody or antibody fragment, and a stress protein domain.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: June 21, 2022
    Assignee: The General Hospital Corporation
    Inventors: Mark C. Poznansky, Jeffrey A. Gelfand
  • Modulation of immune response using BTLA agonist antibodies
    Patent number: 11352428
    Abstract: The present invention relates to the seminal discovery that BTLA agonist antibodies modulate the immune system. Specifically, the present invention provides antibodies which bind BTLA in the activated state enhancing BTLA signaling. The present invention further provides methods of treating immune and inflammatory diseases and disorders with a BTLA agonist antibody.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: June 7, 2022
    Assignee: Sanford Burnham Prebys Medical Discovery Institute
    Inventors: Carl F. Ware, John Sedy, Paula Norris